Brussels, 05/07/2010 (Agence Europe) - The number of patent settlements in the pharmaceutical sector that are potentially problematic under the European Union's antitrust rules fell to 10% of total patent settlements (9 out of 93) in the sector in the period July 2008 to December 2009 compared with 22% in the period covered in last year's inquiry into the pharmaceutical industry (January 2000-June 2008). The amount of money involved in the settlements, between the so-called "originator"...